View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 17, 2020

Inovio to begin Phase II segment of Covid-19 vaccine trial

Biotech firm Inovio is set to go ahead with the Phase II segment of its planned Phase II/III trial of its Covid-19 vaccine candidate, INO-4800, following clearance from the US Food and Drug Administration (FDA).

Biotech firm Inovio is set to go ahead with the Phase II segment of its planned Phase II/III trial of its Covid-19 vaccine candidate, INO-4800, following clearance from the US Food and Drug Administration (FDA).

INO-4800 is a DNA vaccine candidate that can potentially provide protection against the SARS-CoV-2 virus that causes Covid-19.

The vaccine candidate is stable at room temperature for over a year and does not require freezing in the transport of storage.

The INOVIO INO-4800 Vaccine Trial for Efficacy (INNOVATE) randomised, blinded, placebo-controlled safety and efficacy trial will be conducted in adults in the US.

It will receive funding from the US Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA).

The Phase II segment will analyse the safety, tolerability and immunogenicity of INO-4800 in a two-dose regimen consisting of 1mg or 2mg.

Participants will be categorised into three age groups of 18-50, 51-64, and 65 and older.

They will be randomised in a three-to-one ratio to receive either INO-4800 or placebo for each dose to confirm the appropriate dose(s) for the Phase III efficacy evaluation.

The Phase III segment is on partial clinical hold as the FDA sought to resolve queries on the CELLECTRA 2000 device that will be used to deliver INO-4800 directly into the skin.

The company anticipates resolving the remaining device questions during the conduct of the Phase II segment and before initiating the Phase III segment of the trial.

Inovio president and CEO Dr Joseph Kim said: “INO-4800’s key differentiators are the safety and tolerability data we have observed thus far, as well as its excellent thermostability profile, making it possible to manufacture at scale and transport without frozen cold chain requirements.

“INO-4800 also maintains the ability to be safely re-administered and is differentiated by its ability to stimulate both CD4+ and CD8+ T cell responses.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU